glp receptor 1 agonists GLP-1 as Treatments for Type 2 Diabetes Glucagon-like peptide 1(GLP-1) receptor agonists
Description
Clinical guidelines are expanding to recommend GLP-1 therapies for this group, supported by evidence showing effective weight loss and metabolic benefits at this stage
For this reason, it is also referred to as non-alcoholic steatohepatitis (NASH)
In addition, increased mortality risk is from selected wealthy high-income settings disease specific from disease specific populations and not from a more generalized global cohort
Ozempic is a stronger drug
Thus, fluctuations in the levels of E
Collins L, Costello RA
